RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

Voluntary Announcement

NMPA APPROVES THE CLINICAL TRIAL OF BISPECIFIC ANTIBODY-DRUG CONJUGATE (BISPECIFIC ADC) RC288 FOR INJECTION

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the "**Company**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has received the Notice of Approval for Clinical Trials of Drug issued by the National Medical Products Administration of the People's Republic of China (the "**NMPA**"). The Phase I/IIa clinical trial of RC288 (Drug name: RC288 for injection, acceptance number: CXSL2600288), a bispecific antibody-drug conjugate (bispecific ADC) independently developed by the Company, for the monotherapy of locally advanced unresectable or metastatic malignant solid tumors, has been approved.

Pursuant to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, RC288 for injection complies with the relevant requirements for drug registration. The conduct of clinical trials of this drug as monotherapy in patients with advanced malignant solid tumors is approved by the NMPA.

RC288 is a bispecific antibody-drug conjugate (ADC) targeting both PSMA and B7H3, an innovative drug molecule developed by the Company using next-generation conjugation and toxin technologies. PSMA, stands for prostate-specific membrane antigen, a type II transmembrane glycoprotein that supports tumor growth and angiogenesis. B7H3 is an immune checkpoint molecule; when overexpressed in tumors, it promotes immune escape and tumor progression.

Both PSMA and B7H3 are promising therapeutic targets, highly expressed in a variety of malignant tumor tissues and tumor neovascularization, and are involved in signaling pathways related to tumor proliferation, invasion and drug resistance.

In accordance with the relevant laws and regulations governing drug registration in China, after obtaining approval for its clinical trial application, a drug may only be marketed and sold upon completion of clinical trials and further approval by the NMPA. The approval of this clinical trial will not have a material impact on the Company's recent performance.

Given the high-tech, high-risk and high value-added characteristics of pharmaceutical products, the early-stage research and development of drugs, as well as the long cycle and numerous procedures from drug development, clinical trial approval to production, are susceptible to various uncertainties. Investors are advised to make prudent investment decisions and pay attention to risk prevention.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The People's Republic of China
April 1, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*